Rothschild Investment LLC Makes New $137,000 Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Rothschild Investment LLC purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 2nd quarter, Holdings Channel.com reports. The fund purchased 282 shares of the company’s stock, valued at approximately $137,000.

A number of other large investors also recently made changes to their positions in the business. Riverview Trust Co acquired a new position in IDEXX Laboratories in the first quarter valued at $26,000. Crewe Advisors LLC purchased a new position in shares of IDEXX Laboratories during the 1st quarter worth about $26,000. Ridgewood Investments LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter worth approximately $27,000. Institutional & Family Asset Management LLC purchased a new stake in IDEXX Laboratories in the second quarter valued at approximately $28,000. Finally, DSM Capital Partners LLC acquired a new position in IDEXX Laboratories during the fourth quarter worth approximately $33,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $469.01 on Wednesday. The business’s 50-day simple moving average is $480.93 and its 200 day simple moving average is $505.29. The company has a market cap of $38.73 billion, a P/E ratio of 45.40, a PEG ratio of 4.10 and a beta of 1.32. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.01 billion. IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The company’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.67 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 10.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. Morgan Stanley reduced their target price on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a report on Tuesday, May 14th. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday, June 24th. BTIG Research initiated coverage on IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective on the stock. Finally, StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $582.25.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.